Ceftibuten

Generic name
Ceftibuten
Brand name
ATC Code
J01DD14
Compare …

Ceftibuten

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information for use in children

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Pharyngitis with or without tonsillitis, middle ear inflammation, complicated or uncomplicated lower urinary tract infections
  • Oral
    • ≥ 3 months and < 45 kg
      • 9 mg/kg/day in 1 dose. Max: 400 mg/day.
      • Directions for administration:

        The tablets and the suspension should both be taken at least 2 hours before a meal.

    • ≥ 45 kg
      • 400 mg/day in 1 dose
      • Directions for administration:

        The tablets and the suspension should both be taken at least 2 hours before a meal.

Renal impaiment in children > 3 months

Adjustment in renal impairment as specified:

GFR 50-80 ml/min/1.73 m2
Dose adjustment is not required
GFR 30-50 ml/min/1.73 m2
50 percentage of single dose and dosing interval : 24 uur
Maximum 200 mg/day
GFR 10-30 ml/min/1.73 m2
25 percentage of single dose and dosing interval : 24 uur
Maximum 100 mg/day
GFR < 10 ml/min/1.73 m2
Generalized recommendations cannot be given.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Uncommon (0.1-1%): Diaper dermatitis. Dysuria, hematuria.
Very rare (<0.01%): : irritability, agitation, somnolence, insomnia, chills

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

The safety and efficacy in children younger than 3 months have not been determined.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

OTHER BETA-LACTAM ANTIBACTERIALS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

First-generation cephalosporins
J01DB05
J01DB04
J01DB01
J01DB03
Second-generation cephalosporins
J01DC04
J01DC03
J01DC02
Third-generation cephalosporins
J01DD08
J01DD01
J01DD13
J01DD52
J01DD02
J01DD04
Fourth-generation cephalosporins
J01DE01
Monobactams
J01DF01
Carbapenems
J01DH03
J01DH51
J01DH02
MONOBACTAMS
J01DF01
Other cephalosporins and penems
J01DI02

References

  1. Merck Sharp & Dohme BV, SPC Cedax (RVG 15747) 30-1-2015, www.geneesmiddeleninformatiebank.nl, Geraadpleegd 28 okt 2016
  2. Nederlandse Vereniging voor Kindergeneeskunde, Richtlijn Urineweginfecties bij kinderen, www.nvk.nl, 09 juni 2010

Changes

Therapeutic Drug Monitoring


Overdose